Updates on Outcome of Board Meeting (Delisting from MSE)
Orchid Chemicals & Pharmaceuticals Ltd has informed BSE that the Board of Directors of the Company at its meeting held on July 14, 2014 has approved the delisting of the equity shares from (MSE) Madras Stock Exchange Limited, pursuant to voluntary de recognition and exit of MSE as per the Securities and Exchange Board of India's (SEBI) circular dated May 30, 2012. Outcome of Board Meeting
Orchid Chemicals & Pharmaceuticals Ltd has informed BSE that the Board of Directors of the Company at its meeting held on July 14, 2014, has approved the issue of shares to Promoters on a preferential basis pursuant to the conditions of CDR package sanctioned to the Company by Corporate Debt Restructuring Cell. The consent for the same from the shareholders is being sought through Postal Ballot for which the notice will be sent shortly. Orchid receives US FDA approval for Eszopiclone Tablets ANDA
Orchid Chemicals & Pharmaceuticals Ltd has informed BSE regarding a Press Release dated June 19, 2014 titled "Orchid receives US FDA approval for Eszopiclone Tablets ANDA". Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
R Vijayalakshmi has submitted the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 to BSE Clarification
With reference to increase in volume, Orchid Chemicals & Pharmaceuticals Ltd has Clarified to BSE as under:"the share price and trading volumes of Orchid Chemicals & Pharmaceuticals Ltd have witnessed an increase over the last few days which are, in the company's opinion completely market driven. Further, we confirm that there are no material developments and plans other than those already communicated to the exchanges in line with the listing... Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
R Vijayalakshmi has submitted the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 to BSE Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
K Raghavendra Rao has submitted the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 to BSE Outcome of Board Meeting
Orchid Chemicals & Pharmaceuticals Ltd has informed BSE that Shri. K. N. Venkatasubramanian, (Non-Executive, Independent Director) has been designated as the Chairman of the Company and consequent to this, Shri K. Raghavendra Rao has been re-designated as the Managing Director of the Company.The above have been approved by the Board at its meeting held on May 12, 2014. Financial Results with Results Press Release & Limited Review for March 31, 2014
Orchid Chemicals & Pharmaceuticals Ltd has informed BSE about the Financial Results, Results Press Release & a copy of the Limited Review Report for the period ended March 31, 2014. Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
K Raghavendra Rao has submitted the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 to BSE